By analyzing blood plasma samples taken at several time points, ISB researchers have identified specific proteins that persistently presented as outliers and signaled metastatic cancer well before patients were diagnosed. The findings were published in the journal Scientific Reports.
Diseases develop gradually over years, sometimes decades, before symptoms appear, and are due to malfunctioning physiological processes brought about by our genes and environment. In research published in the journal Proceedings of the National Academy of Sciences (PNAS), ISB researchers have shown how an individual’s genetic risk for disease is often reflected in their blood.
There is a dichotomy between Bacteroides- and Prevotella-dominated guts — two common gut bacterial genera — and there is a significant barrier when it comes to transitioning from one to the other.
Dr. Nathan Price has been inducted into the American Institute for Medical and Biological Engineering’s (AIMBE) College of Fellows. Price was nominated, reviewed, and elected by peers and members of the College of Fellows for his contributions deriving medical and biological insights from large-scale data analysis and network modeling, and translating those insights to society.
Predicting the alpha diversity of an individual’s gut microbiome is possible by examining metabolites in the blood. The robust relationship between host metabolome and gut microbiome diversity opens the door for a fast, cheap and reliable blood test to identify individuals with low gut diversity.